Advanced Cardiovascular Testing: ApoB, Lp(a), CAC and More
Three tests change decisions and are commonly omitted from standard panels. Several expensive ones add little. Here is which is which, and when imaging is worth it.
The Short Answer
A standard lipid panel measures total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. Three additions change decisions materially: apolipoprotein B, which counts atherogenic particles rather than the cholesterol they carry; lipoprotein(a), which is an independent causal risk factor most people have never had measured; and, in the right circumstances, a coronary artery calcium score, which measures disease rather than risk. Most of what else is sold as advanced testing adds cost without adding a decision.
Apolipoprotein B
Every atherogenic lipoprotein particle carries exactly one apolipoprotein B molecule, so measuring apoB counts particles. Since the causal exposure in atherosclerosis is particle entry into the arterial wall, apoB measures the exposure more directly than LDL cholesterol does.
The practical case for measuring it is discordance. LDL cholesterol and apoB agree in most people and diverge in a substantial minority, particularly those with insulin resistance, high triglycerides or small dense particles. In discordant cases apoB tracks risk better, which means a person with an acceptable LDL cholesterol and an elevated apoB is being reassured by the wrong number.
It is inexpensive, standardised, does not require fasting, and is not on most standard panels. Non-HDL cholesterol, computed by subtracting HDL from total cholesterol, is a reasonable free proxy that correlates well with apoB and can be derived from any existing panel.
Guideline positions increasingly recognise apoB as a preferred measure, and clinical practice has been slower to adopt it than the evidence supports. Asking for it is often the only way it gets measured.
Lipoprotein(a)
Lp(a) is an LDL-like particle with an additional apolipoprotein(a) attached. Its concentration is roughly 80 to 90 per cent genetically determined, stable through life, and largely unresponsive to diet, exercise or statins.
It is an independent causal risk factor for atherosclerotic cardiovascular disease and for aortic valve stenosis, supported by genetic evidence rather than only observational association. Roughly one in five people has an elevated level, and most have never been tested.
Measure once. Because it is genetically determined and stable, a single measurement generally suffices for life. Units vary between laboratories, nmol/L being preferred over mg/dL, which matters when comparing results.
What to do with an elevated result. There is no approved therapy specifically lowering Lp(a) yet, though agents are in late-stage trials. What changes is the urgency of everything else: apoB reduction, blood pressure, smoking cessation and glycaemic control all become more consequential, and earlier intervention is more justified. It is also a reason to inform first-degree relatives, since it is inherited.
This is the single most under-ordered test in cardiovascular risk assessment, and the argument for it is that a person with high Lp(a) should know before rather than after an event.
Coronary Artery Calcium and Imaging
| Test | What it measures | When it helps |
|---|---|---|
| Coronary artery calcium score | Calcified plaque burden; a measure of disease, not risk | Intermediate risk where a medication decision is genuinely uncertain |
| CT coronary angiography | Luminal narrowing and non-calcified plaque | Symptomatic assessment; clinical indication |
| Carotid ultrasound with intima-media thickness | Wall thickness and plaque in carotids | Sometimes as a risk refinement; less standardised |
| Ankle-brachial index | Peripheral arterial disease | Where peripheral symptoms or high risk |
| Stress testing | Inducible ischaemia | Symptomatic patients; not a screening tool in asymptomatic people |
| Echocardiography | Structure and function | Clinical indication rather than screening |
A calcium score of zero in an asymptomatic person at intermediate risk carries a favourable short-to-medium term prognosis and can reasonably support deferring medication, while a high score reclassifies a person upward and supports acting. That reclassification is the value: it is worth doing when the result would change what you do, and not otherwise.
Two caveats. It involves ionising radiation, at a low dose. And it detects calcified plaque, so soft non-calcified plaque, which is arguably more prone to rupture, is not captured. A zero score is reassuring rather than a guarantee, particularly in younger people.
What Adds Little
LDL particle number by NMR, where apoB is available. It measures a similar quantity at higher cost with less standardisation.
Extensive lipid subfraction panels. Detailed subclass breakdowns rarely change management beyond what apoB and triglycerides already indicate.
Oxidised LDL, myeloperoxidase, Lp-PLA2. Mechanistically interesting, limited clinical validation for routine use, and they seldom change a decision.
Homocysteine, for cardiovascular purposes. Lowering it with B vitamins did not reduce events in large trials. It remains relevant to B vitamin status and to some other contexts.
Genetic risk scores, currently. Interesting, improving, and rarely changing management beyond what family history and Lp(a) already convey.
Repeat calcium scoring at short intervals. Progression measurement is a research question, and the score is not a monitoring tool for whether a statin is working.
The general test for whether an advanced test is worth ordering: name the two possible results and what you would do differently for each. If the answer is the same, the test is information rather than a decision.
A Sensible Testing Sequence
Everyone, once, from early adulthood: a standard lipid panel plus apolipoprotein B, plus lipoprotein(a) once in a lifetime. HbA1c, fasting insulin or triglyceride to HDL ratio, hs-CRP, and properly measured home blood pressure.
Add family history properly. Premature cardiovascular disease in first-degree relatives, meaning before 55 in men and 65 in women, changes risk assessment materially and is free to establish.
Repeat the modifiable markers at three to six months after an intervention, then annually.
Consider a calcium score where risk is intermediate, you are over 40, and a medication decision genuinely hangs on the result. This is a clinical conversation, not a self-ordered test in most places.
Escalate clinically for: chest pain or exertional symptoms, an elevated apoB that is not responding, blood pressure persistently above threshold, elevated Lp(a) with family history, or a first-degree relative with premature disease.
The pattern worth noticing is that the three highest-value additions, apoB, Lp(a) and properly measured home blood pressure, are all inexpensive, and the expensive tests mostly refine rather than redirect.
Interpreting Against Targets Rather Than Ranges
Cardiovascular markers differ from most laboratory results in an important way: reference ranges describe a population in which cardiovascular disease is the leading cause of death, so being average is not a target.
For apoB, lower is better across the observed range, and there is no established threshold below which further reduction stops helping in people at risk. Guideline targets vary by risk category and are considerably lower for people with established disease. A result flagged as normal by a laboratory can be well above what would be appropriate for a person with elevated Lp(a) and a family history.
This is where risk context and marker value have to be interpreted together. The same apoB carries different implications depending on age, Lp(a), blood pressure, glycaemic status and family history, and the cumulative nature of the exposure means a value held for thirty years matters more than the value itself.
Which is the argument for measuring early, knowing your fixed factors once, and tracking the modifiable ones consistently rather than elaborately.
The AEONNN Perspective
AEONNN's position in Pillar 4 testing is that three inexpensive additions do most of the work and that the expensive panels rarely change a decision. The Consensus layer supports apolipoprotein B as the preferred exposure measure and lipoprotein(a) as a once-in-a-lifetime measurement, and clinical practice has adopted both more slowly than the evidence warrants.
The Quality layer matters in a specific way here: Lp(a) units differ between laboratories, with nmol/L preferred over mg/dL, and comparing results across units produces artefacts. ApoB is well standardised, which is part of why the platform prefers it to NMR particle counts.
Two interpretive positions follow from the Population layer. Reference ranges describe a population in which cardiovascular disease is the leading cause of death, so average is not a target. And the same apoB means different things depending on age, Lp(a), blood pressure and family history, because the exposure is cumulative. That is why AEONNN reads Pillar 4 markers against a member's risk context rather than against a laboratory flag, and why the platform's test for any advanced test is whether the two possible results would change what happens next.
Pillar Matrix mapping
Database Matrix layers
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Quality / Formulation Layer (ConsumerLab, Labdoor)
- Population Layer (UK Biobank, NHANES)
Frequently Asked
What is apoB and why measure it?
Apolipoprotein B counts atherogenic particles, since each carries exactly one apoB molecule. It measures the causal exposure more directly than LDL cholesterol, and the two diverge in a substantial minority of people.
Is non-HDL cholesterol a good substitute?
It is a reasonable free proxy that correlates well with apoB and can be computed from any existing panel by subtracting HDL from total cholesterol.
Should I test lipoprotein(a)?
Yes, once. It is roughly 80 to 90 per cent genetically determined, stable through life, an independent causal risk factor, elevated in about one in five people, and rarely measured.
What do I do about high Lp(a)?
No approved therapy specifically lowers it yet. What changes is the urgency of everything else: apoB reduction, blood pressure, smoking cessation and glycaemic control. It is also worth informing first-degree relatives.
When is a coronary calcium score useful?
At intermediate risk, over 40, where a medication decision genuinely hangs on the result. A zero score can support deferring medication; a high score supports acting.
What are the limits of a calcium score?
It uses low-dose ionising radiation and detects only calcified plaque, so soft non-calcified plaque is not captured. A zero score is reassuring rather than a guarantee, particularly in younger people.
Which advanced tests are not worth it?
NMR particle number where apoB is available, extensive subfraction panels, oxidised LDL, myeloperoxidase, Lp-PLA2, and homocysteine for cardiovascular purposes specifically.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.